Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Target Fortification of Breast Milk: How Often Breast Milk Needs to be Measured? (TFO2)

10 de agosto de 2016 actualizado por: Christoph Fusch, McMaster Children's Hospital

Target Fortification of Breast Milk: The Effect of Different Schedules for Milk Analysis on the Growth and Development of Preterm Infants.

It has been observed that target fortification on different schedules leads to meal to meal variation. It changes the ratio of protein to energy and the percentage of carbohydrate to non-protein energy which may, affect growth. In the past, the investigators have analyzed the outcomes of breast milk composition when target fortification is done with different analysis schedules. The investigators were able to measure the macronutrient intake for different milk analysis schedules via a theoretical model and show that the more frequent schedules reduce the variation of fortified-breast milk, whereas a reduced schedule leads to a high variation of macronutrients. It was observed that, in all the breast milk samples measured twice per week, infants achieved on average the recommended macronutrients in line with current recommendations. Nonetheless, the model only looks at the macronutrient intake and does not investigates the relationship between macronutrient variation and its effect on growth.

The aim of the current study is to compare a frequent schedule of measurement of macronutrient analysis with a reduced schedule of measurement and to study its affect on growth, protein accretion and metabolic parameter.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Anticipado)

56

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Christoph Fusch, MD, PhD
  • Número de teléfono: 75721 +1 521 2100
  • Correo electrónico: fusch@mcmaster.ca

Copia de seguridad de contactos de estudio

  • Nombre: Niels Rochow, MD
  • Número de teléfono: 23106 +1 521 2100
  • Correo electrónico: rochow@mcmaster.ca

Ubicaciones de estudio

    • Ontario
      • Hamilton, Ontario, Canadá, L8S 4K1
        • Faculty of Health Science, McMaster Children's Hospital
        • Contacto:
          • Christoph Fusch, MD, PhD, FRCPC
          • Número de teléfono: 75721 +1 905 521 2100
          • Correo electrónico: fusch@mcmaster.ca
        • Investigador principal:
          • Christoph Fusch, MD, PhD, FRCPC
        • Sub-Investigador:
          • Niels Rochow, MD
        • Sub-Investigador:
          • Gerhard Fusch, PhD
        • Sub-Investigador:
          • Salhab el Helou, MD, FRCPC
        • Sub-Investigador:
          • Sabiha Ahmad
        • Sub-Investigador:
          • Akshdeep Singh Bhatia
        • Sub-Investigador:
          • Klaus Wutzke, PhD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

No mayor que 6 meses (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Gestational age < 30 weeks (maternal dates or early fetal ultrasound);
  2. Tolerating an enteral intake of ≥100 mL/kg/d for ≥ 24h;
  3. Subject is anticipated to receive the intervention for ≥ 3 consecutive weeks after full enteral feeding (≥150 mL/kg/d) has been achieved;
  4. Written informed consent has been obtained from the infant's legal representative.
  5. Multiple births: Each infant will be included in the study if he/she meets the study criteria, and siblings will be individually randomized to one or other of the treatment arms.
  6. Discussion with Most Responsible Physician (MRP) and the staff in order to discuss any potential transfer during the next 7 days.

Exclusion Criteria:

  1. Gastrointestinal malformation, major congenital anomalies and chromosomal abnormalities;
  2. Babies with enterostoma or short gut syndrome;
  3. Infants fed more than 25% of mean caloric intake for a consecutive week with formula milk;
  4. Fluid restriction <140 mL/kg/d for ≥ 3 consecutive days;
  5. Sepsis - all infants with gram-negative sepsis will be removed from the study;
  6. Necrotizing enterocolitis, defined by feeding intolerance associated with positive x-ray findings (pneumatosis intestinalis - Bell Stage 2; air in the biliary tract or free air in the peritoneum - Bell Stage 3);
  7. Renal disease, defined by symptoms (oliguria, anuria, proteinuria, hematuria) associated with an increased blood urea nitrogen >10 mmol/L and creatinine of 130mmol/L
  8. Participation in another clinical trial that may provide an alternative nutritional intervention, which might affect the outcomes of this study. outcomes of this study;
  9. Probability of transfer to another neonatal intensive care unit or level II nursery outside the McMaster Children's Hospital, as discussed with the most responsible physician (MRP)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: 5 milk analysis
  1. Macronutrient content (for protein, carbohydrate and fat content) will be analyzed five times per week, of native breast milk batches which had been prepared for 24 hours feeding.
  2. Routine fortifier will be added to breast milk batches.
  3. Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level.
Modular product supplementation is based on most recent breast analysis done for the participant.
Modular product supplementation is based on most recent breast analysis done for the participant.
Modular product supplementation is based on most recent breast analysis done for the participant.
Experimental: 1 milk analysis
  1. Macronutrient content (for protein, carbohydrate and fat content) will be analyzed once per week of native breast milk batches which had been prepared for 24 hours feeding.
  2. Routine fortifier will be added to breast milk batches.
  3. Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level.
Modular product supplementation is based on most recent breast analysis done for the participant.
Modular product supplementation is based on most recent breast analysis done for the participant.
Modular product supplementation is based on most recent breast analysis done for the participant.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
Growth during first three weeks of intervention
Periodo de tiempo: first three weeks during intervention before 36 weeks of gestation
first three weeks during intervention before 36 weeks of gestation

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Daily Nutrient intake (kcal, lactose, protein, fat) measured with conventional milk analysis
Periodo de tiempo: from inclusion at postmenstrual age <30 weeks until 36 weeks of gestation
from inclusion at postmenstrual age <30 weeks until 36 weeks of gestation
Weight Gain
Periodo de tiempo: from inclusion at postmenstrual age <30 weeks until 36 weeks of gestation or discharge
from inclusion at postmenstrual age <30 weeks until 36 weeks of gestation or discharge
Oxidative stress by 8-Oxo-2'-deoxyguanosine metabolites in urine
Periodo de tiempo: from inclusion at postmenstrual age <30 weeks until discharge
Measured by mass spectroscopy
from inclusion at postmenstrual age <30 weeks until discharge
Protein synthesis analyzed by nitrogen excretion in urine [µmol/mL]
Periodo de tiempo: first three weeks during intervention before 36 weeks of gestation
first three weeks during intervention before 36 weeks of gestation
Feeding intolerance questionaire
Periodo de tiempo: from inclusion at postmenstrual age <30 weeks until discharge
volume of gastric residuals, color of gastric residuals, vomiting, abdominal girth, abdominal distention
from inclusion at postmenstrual age <30 weeks until discharge
Fat mass [g]
Periodo de tiempo: from inclusion at postmenstrual age <30 weeks until discharge
Measured with bioelectrical impedance analysis
from inclusion at postmenstrual age <30 weeks until discharge
Lean mass [g]
Periodo de tiempo: from inclusion at postmenstrual age <30 weeks until discharge
Measured with bioelectrical impedance analysis
from inclusion at postmenstrual age <30 weeks until discharge
Head circumference [cm]
Periodo de tiempo: from inclusion at postmenstrual age <30 weeks until discharge
Measured by tape
from inclusion at postmenstrual age <30 weeks until discharge
Body length [cm]
Periodo de tiempo: from inclusion at postmenstrual age <30 weeks until discharge
Measured by length board
from inclusion at postmenstrual age <30 weeks until discharge

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Christoph Fusch, MD, PhD, McMaster Children's Hospital

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de septiembre de 2016

Finalización primaria (Anticipado)

1 de junio de 2017

Finalización del estudio (Anticipado)

1 de junio de 2019

Fechas de registro del estudio

Enviado por primera vez

8 de agosto de 2016

Primero enviado que cumplió con los criterios de control de calidad

10 de agosto de 2016

Publicado por primera vez (Estimar)

15 de agosto de 2016

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

15 de agosto de 2016

Última actualización enviada que cumplió con los criterios de control de calidad

10 de agosto de 2016

Última verificación

1 de agosto de 2016

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • 2016TFO2

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Trastorno del crecimiento posnatal

3
Suscribir